ArticlePharmacoepidemiology and drug safety2013
Calendar time-specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy.
Article in Pharmacoepidemiology and drug safety, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Proton Pump Inhibitors and Gastric Cancer: A Large-Scale Propensity Score-Matched Analysis.Gut and liver · 2026Article
- Active Comparator New User Cohort Studies and Matching.JAMA internal medicine · 2026Article
- Investigating the association between incretin-based therapies and thyroid cancer incidence among US Medicare beneficiaries with diabetes.BMJ open diabetes research & care · 2025Article
- Proton pump inhibitors and all-cause mortality risk among cancer patients.World journal of clinical oncology · 2025Article
- Design and analysis of outcomes following SARS-CoV-2 infection in veterans.BMC medical research methodology · 2023Article
- Comparative Effectiveness of Ticagrelor, Prasugrel, and Clopidogrel for Secondary Prophylaxis in Acute Coronary Syndrome: A Propensity Score-Matched Cohort Study.Clinical pharmacology and therapeutics · 2023Article
- Comparative Risk of Hospitalized Bleeding of P2Y12 Inhibitors for Secondary Prophylaxis in Acute Coronary Syndrome After Percutaneous Coronary Intervention.Clinical pharmacology and therapeutics · 2023Article
- Adaptability of High Dimensional Propensity Score Procedure in the Transition from ICD-9 to ICD-10 in the US Healthcare System.Clinical epidemiology · 2023Article
- Noninterventional studies in the COVID-19 era: methodological considerations for study design and analysis.Journal of clinical epidemiology · 2023Article
- Integrase Strand Transfer Inhibitors Are Associated With Incident Diabetes Mellitus in People With Human Immunodeficiency Virus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Angiotensin-converting enzyme inhibitors and risk of age-related macular degeneration in individuals with hypertension.British journal of clinical pharmacology · 2022Article
- Potential Channeling Bias in the Evaluation of Cardiovascular Risk: The Importance of Comparator Selection in Observational Research.Pharmaceutical medicine · 2022Observational
- Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Acute Pancreatitis: A Population-Based Cohort Study.Drug safety · 2022Article
- Incidence of venous thromboembolism following initiation of non-steroidal anti-inflammatory drugs in U.S. women.Rheumatology (Oxford, England) · 2020Observational
- Brief Report: Integrase Strand Transfer Inhibitors Are Associated With Lower Risk of Incident Cardiovascular Disease in People Living With HIV.Journal of acquired immune deficiency syndromes (1999) · 2020Article
- Matching with time-dependent treatments: A review and look forward.Statistics in medicine · 2020Review
- Optimal Timing of Physician Visits after Hospital Discharge to Reduce Readmission.Health services research · 2018Article
- Data-Adaptive Estimation for Double-Robust Methods in Population-Based Cancer Epidemiology: Risk Differences for Lung Cancer Mortality by Emergency Presentation.American journal of epidemiology · 2018Article
- Assessment of channeling bias among initiators of glucose-lowering drugs: A UK cohort study.Clinical epidemiology · 2017Article
- Comparative Effectiveness of Oxaliplatin Versus 5-flourouricil in Older Adults: An Instrumental Variable Analysis.Epidemiology (Cambridge, Mass.) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeNonexperimental studies of treatment effectiveness provide an important complement to randomized trials by including heterogeneous populations. Propensity scores (PSs) are common in these studies but may not adequately capture changes in channeling experienced by innovative treatments. We use calendar time-specific (CTS) PSs to examine the effect of oxaliplatin during dissemination from off-label to widespread use.
methodsStage III colon cancer patients aged 65+ years initiating chemotherapy between 2003 and 2006 were examined using cancer registry data linked with Medicare claims. Two PS approaches for receipt of oxaliplatin versus 5-flourouricil were constructed using logistic models with key components of age, sex, substage, grade, census-level income, and comorbidities: (i) a conventional, year-adjusted PS and (ii) a CTS PS constructed and matched separately within 1-year intervals, then combined. We compared PS-matched hazard ratios (HRs) for mortality using Cox models.
resultsOxaliplatin use increased significantly; 8% (n = 86) of patients received it in the first time period versus 52% (n = 386) in the last. Channeling by comorbidities, income, and age appeared to change over time. The CTS PS improved covariate balance within calendar time strata and yielded an attenuated estimated benefit of oxaliplatin (HR = 0.75) compared with the conventional PS (HR = 0.69).
conclusionIn settings where prescribing patterns have changed and calendar time acts as a confounder, a CTS PS can characterize changes in treatment choices and estimating separate PSs within specific calendar time periods may result in enhanced confounding control. To increase validity of comparative effectiveness research, researchers should carefully consider drug lifecycles and effects of innovative treatment dissemination over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.